Latest news with #Iambic
Yahoo
3 days ago
- Business
- Yahoo
Iambic Named to CNBC's 2025 Disruptor 50 List
SAN DIEGO, June 10, 2025--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced today that it has been named to the annual CNBC Disruptor 50 list, which recognizes the most innovative private companies transforming industry. "While many companies are building AI models for drug discovery, Iambic stands alone in terms of successfully and rapidly delivering new medicines to human clinical trials," said Tom Miller, PhD, Iambic's co-founder and CEO. "Our industry-leading models design breakthrough molecular structures that unlock challenging targets, de-risk development by predicting human response early in discovery, and accelerate the delivery of both first-in-class and best-in-class drug candidates across multiple disease areas." Iambic's drug discovery platform integrates predictive modeling with automated experimentation, streamlining the pathway from discovery to clinical studies. Its lead oncology drug candidate went from program initiation to human trials in just two years, taking four years off the industry average, with a clinical data readout expected later this year. Independently and with partners, Iambic is advancing a pipeline of drug candidates for cancer and neurological diseases. Iambic recently announced advances to its two core AI drug discovery models. Enchant is the leading model for predicting clinical properties of potential drug molecules in humans, helping reduce the time, expense and risk of drug development. NeuralPLexer, which is used to predict the 3D structures of protein-ligand complexes, is faster and more accurate than AlphaFold3, giving researchers instant insights across protein classes and drug molecules to identify new drug candidates at unprecedented speed and scale. "We are working to redefine how medicines are discovered, developing AI and machine learning to increase efficiency by understanding the viability of new molecules before they enter pre-clinical and clinical studies, in turn reducing the time and cost of developing breakthrough treatments," said Fred Manby, PhD, Iambic's Chief Technology Officer and Co-Founder. "Further, we are lowering clinical trial risk and patient burden by using AI to predict drug behavior before human testing and demonstrating how computational models can help regulators accelerate drug approvals." The annual CNBC Disruptor 50 list showcases today's most forward-thinking and ambitious companies leading the way in innovation and industry transformation. Each submission underwent a thorough evaluation process, incorporating extensive research and analysis based on quantitative and qualitative metrics. Input from CNBC's editorial team and a diverse panel of entrepreneurial experts further informed the selection process. For the complete list of CNBC Disruptor 50 companies, visit About Iambic's AI-Driven Discovery Platform The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant (multimodal transformer model that predicts clinical and preclinical endpoints) and NeuralPLexer (best-in-class predictor of protein and protein-ligand structures). The integration of physics principles into the platform's AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multiparameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated chemical synthesis and experimental execution, Iambic completes design-make-test cycles on a weekly cadence. About Iambic Therapeutics Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and in partnership, to address urgent unmet patient need. Learn more about the Iambic team, platform, pipeline, and partnerships at View source version on Contacts media@
Business Wire
3 days ago
- Business
- Business Wire
Iambic Named to CNBC's 2025 Disruptor 50 List
SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced today that it has been named to the annual CNBC Disruptor 50 list, which recognizes the most innovative private companies transforming industry. 'While many companies are building AI models for drug discovery, Iambic stands alone in terms of successfully and rapidly delivering new medicines to human clinical trials,' said Tom Miller, PhD, Iambic's co-founder and CEO. 'Our industry-leading models design breakthrough molecular structures that unlock challenging targets, de-risk development by predicting human response early in discovery, and accelerate the delivery of both first-in-class and best-in-class drug candidates across multiple disease areas.' Iambic's drug discovery platform integrates predictive modeling with automated experimentation, streamlining the pathway from discovery to clinical studies. Its lead oncology drug candidate went from program initiation to human trials in just two years, taking four years off the industry average, with a clinical data readout expected later this year. Independently and with partners, Iambic is advancing a pipeline of drug candidates for cancer and neurological diseases. Iambic recently announced advances to its two core AI drug discovery models. Enchant is the leading model for predicting clinical properties of potential drug molecules in humans, helping reduce the time, expense and risk of drug development. NeuralPLexer, which is used to predict the 3D structures of protein-ligand complexes, is faster and more accurate than AlphaFold3, giving researchers instant insights across protein classes and drug molecules to identify new drug candidates at unprecedented speed and scale. "We are working to redefine how medicines are discovered, developing AI and machine learning to increase efficiency by understanding the viability of new molecules before they enter pre-clinical and clinical studies, in turn reducing the time and cost of developing breakthrough treatments," said Fred Manby, PhD, Iambic's Chief Technology Officer and Co-Founder. 'Further, we are lowering clinical trial risk and patient burden by using AI to predict drug behavior before human testing and demonstrating how computational models can help regulators accelerate drug approvals.' The annual CNBC Disruptor 50 list showcases today's most forward-thinking and ambitious companies leading the way in innovation and industry transformation. Each submission underwent a thorough evaluation process, incorporating extensive research and analysis based on quantitative and qualitative metrics. Input from CNBC's editorial team and a diverse panel of entrepreneurial experts further informed the selection process. For the complete list of CNBC Disruptor 50 companies, visit About Iambic's AI-Driven Discovery Platform The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant (multimodal transformer model that predicts clinical and preclinical endpoints) and NeuralPLexer (best-in-class predictor of protein and protein-ligand structures). The integration of physics principles into the platform's AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multiparameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated chemical synthesis and experimental execution, Iambic completes design-make-test cycles on a weekly cadence. About Iambic Therapeutics Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and in partnership, to address urgent unmet patient need. Learn more about the Iambic team, platform, pipeline, and partnerships at
CNBC
3 days ago
- Business
- CNBC
26. Iambic Therapeutics
Founders: Tom Miller (CEO), Fred ManbyLaunched: 2020Headquarters: San Diego, CaliforniaFunding: $220 millionValuation: N/AKey Technologies: Artificial intelligence, cloud computing, deep neural networks/deep learning, generative AI, machine learning, robotics, quantum computingIndustry: BiotechPrevious appearances on Disruptor 50 list: 0 It can take 10-15 years for today's biopharmaceutical companies to bring new drugs all the way through discovery and clinical trial. San Diego-based Iambic Therapeutics' AI-driven platform can accelerate the pace of drug discovery and development, enabling drug development in just a few years. The company has novel medications in its pipeline to treat breast cancer and other HER2 cancers, and recently formed a research collaboration with pharmaceutical giant Lundbeck for a small molecule therapeutic to treat migraines. By predicting how its new molecules will interact with human systems, Iambic's technology can also reduce the need for clinical trials. The company was originally called Entos, and was founded when CEO Thomas Miller, a theoretical chemist and professor at California Institute of Technology, teamed up with longtime collaborator Fred Manby. In its first iteration, the company worked on making better chemical predictions across many industries and worked with companies including Toyota and Procter & Gamble. But the founders saw applications for their work in what's called small molecule drug discovery. Small molecule drugs, often synthesized chemically, target specific proteins or cellular pathways. Iambic's platform for drug discovery is called Enchant. The company says it provides high-confidence predictions in data-poor situations, such as early-stage and clinical-stage drug programs. "(Cancer) is an area of huge need," Miller told an interviewer for the California Institute of Technology in 2022. "It's an incredibly fast, quickly advancing disease. Many people are afflicted by it. There's many varieties of it. It is the combination of those things that means that if you have the ability to design a new drug, there's a way to … have a relatively fast timescale to advance that to the point where it's in human trials." Rather than selling its drug-discovery services and software to pharmaceutical companies, Iambic has focused on producing its own drugs. "Instead of running around, trying to convince people that this software is so great, and they should buy it, you can actually just use it and execute with it, and actually make better molecules. Then those molecules can stand on their own two feet," Miller said. In 2024, Iambic completed a B round of funding, with investors including OrbiMed, Nvidia and Sequoia Capital, and announced a collaboration with Nvidia, which has been teaming up as a venture investor with many startups across sectors using AI, including, for example, agtech Disruptor Carbon Robotics. Iambic also moved into a new headquarters in San Diego last year and took its headcount to about 100, enabling the company to run experiments on thousands of newly discovered molecules each week. It also announced an update to NeuralPLexer, which predicts protein-ligand structures, and published data in Nature Machine Intelligence showing that NeuralPLexer outperformed AlphaFold, the Nobel Prize in Chemistry winner developed by Google's DeepMind. Iambic also hired its first CFO, Michael Secora, who previously worked at publicly held Recursion.
Yahoo
28-05-2025
- Business
- Yahoo
Iambic Therapeutics to Participate in June Investor Conferences
SAN DIEGO, May 28, 2025--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced its participation in the following June investor conferences: Jefferies Global Healthcare Conference - June 3 - 5, 2025 UBS Spring Biotech Conference - June 24, 2025 About Iambic's AI-Driven Discovery Platform The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant (multimodal transformer model that predicts clinical and preclinical endpoints) and NeuralPLexer (best-in-class predictor of protein and protein-ligand structures). The integration of physics principles into the platform's AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multiparameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated chemical synthesis and experimental execution, Iambic completes design-make-test cycles on a weekly cadence. About Iambic Therapeutics Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and in partnership, to address urgent unmet patient need. Learn more about the Iambic team, platform, pipeline, and partnerships at View source version on Contacts media@ Error while retrieving data Sign in to access your portfolio Error while retrieving data
Business Wire
05-05-2025
- Business
- Business Wire
Iambic Announces Enchant v2, its Next Generation AI Model for Predicting the Clinical Viability of Drug Discovery Programs
SAN DIEGO--(BUSINESS WIRE)--Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, published on major advances to Enchant, Iambic's breakthrough multimodal transformer model for predicting clinical and preclinical endpoints related to the drug discovery and development process. This new version of Enchant marks a pivotal advance in the use of large-scale transformers for drug discovery and supports a fundamental hypothesis: with the right model, architecture, and training strategy, one can achieve exceptional predictive power even in the most data-constrained settings. "Enchant is an exceptionally powerful multimodal transformer model for drug discovery and development,' said Fred Manby, Ph.D., Co-Founder and CTO of Iambic. "Enchant was created to make high-confidence predictions in sparse data regimes—where biology is uncertain and clinical data is limited. That setting reflects the real-world challenge of understanding how a novel therapeutic might affect a patient. By enabling higher-confidence predictions around clinical and preclinical endpoints tied to drug design, portfolio prioritization, and trial strategy, we may begin to address the fundamental issue of improving translation and increasing the likelihood of success in clinical trials. With this version of Enchant and those to come, we believe it is poised to help redefine the trajectory of modern medicine." Enchant's predictions around clinical and preclinical endpoints could help address the fundamental issue of how to increase the likelihood of success translating a potential therapeutic to and through clinical trials. This ability complements Iambic's already demonstrated ability to rapidly progress a potential drug into clinical trials. Read more about how Enchant, Iambic's breakthrough multimodal transformer model, can determine the viability of new drug molecules and make high-confidence predictions with sparse data at Enchant v2: Pushing the Boundaries of Predictive Drug Discovery. About Iambic's AI-Driven Discovery Platform The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant (multimodal transformer model that predicts clinical and preclinical endpoints) and NeuralPLexer (best-in-class predictor of protein and protein-ligand structures). The integration of physics principles into the platform's AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multiparameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated chemical synthesis and experimental execution, Iambic completes design-make-test cycles on a weekly cadence. About Iambic Founded in 2020 and headquartered in San Diego, California, Iambic is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform has demonstrated delivery of high-quality, differentiated therapeutics to the clinical stage with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs. Learn more about the Iambic team, platform, and pipeline at
